Home

Publications 2015 - 2013

Prof. Dr. rer. nat. Hans-Georg Rammensee

Publications 2015 - 2013

 


2015

Nalivaiko K, Hofmann M, Kober K, Teichweyde N, Krammer PH, Rammensee HG, Grosse-Hovest L, Jung G. A Recombinant Bispecific CD20×CD95 Antibody With Superior Activity Against Normal and Malignant B-cells. Mol Ther. 2015; Nov 19. doi: 10.1038/mt.2015.209. [Epub ahead of print]

Brooks SE, Bonney SA, Lee C, Publicover A, Khan G, Smits EL, Sigurdardottir D, Arno M, Li D, Mills KI, Pulford K, Banham AH, van Tendeloo V, Mufti GJ, Rammensee HG, Elliott TJ, Orchard KH, Guinn BA. Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS One. 2015; 10(10):e0140483. PubMed

Caron E, Espona L, Kowalewski DJ, Schuster H, Ternette N, Alpízar A, Schittenhelm RB, Ramarathinam SH, Lindestam Arlehamn CS, Chiek Koh C, Gillet LC, Rabsteyn A, Navarro P, Kim S, Lam H, Sturm T, Marcilla M, Sette A, Campbell DS, Deutsch EW, Moritz RL, Purcell AW, Rammensee HG, Stevanovic S, Aebersold R. An open-source computational and data resource to analyze digital maps of immunopeptidomes. Elife. 2015; Jul 8;4. doi: 10.7554/eLife.07661. PubMed

Kowalewski DJ, Stevanovic S, Rammensee HG, Stickel JS. Antileukemia T-cell responses in CLL - We don't need no aberration. Oncoimmunology. 2015; 4(7):e1011527. PubMed

Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L, Kahn S, Nelde A, Stroh T, Handel M, Kohlbacher O, Kanz L, Salih HR, Rammensee HG, Stevanović S. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood. 2015; 126(10):1203-13. (Erratum in: Blood. 2015; 126(17):2072-3). PubMed

Pasquevich KA, Bieber K, Günter M, Grauer M, Pötz O, Schleicher U, Biedermann T, Beer-Hammer S, Bühring HJ, Rammensee HG, Zender L, Autenrieth IB, Lengerke C, Autenrieth SE. Innate immune system favors emergency monopoiesis at the expense of DC-differentiation to control systemic bacterial infection in mice. Eur J Immunol. 2015; 45(10):2821-33. PubMed

Gouttefangeas C, Chan C, Attig S, Køllgaard TT, Rammensee HG, Stevanović S, Wernet D, thor Straten P, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunol Immunother. 2015; 64(5):585-98. PubMed

Griessinger CM, Maurer A, Kesenheimer C, Kehlbach R, Reischl G, Ehrlichmann W, Bukala D, Harant M, Cay F, Brück J, Nordin R, Kohlhofer U, Rammensee HG, Quintanilla-Martinez L, Schaller M, Röcken M, Pichler BJ, Kneilling M. 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc Natl Acad Sci U S A. 112(4):1161-6, 2015. PubMed

Durben M, Schmiedel D, Hofmann M, Vogt F, Nübling T, Pyz E, Bühring HJ, Rammensee HG, Salih HR, Große-Hovest L, Jung G. Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia. Mol Ther. 2015; 23(4):648-55. PubMed

Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 112(2):E166-75, 2015. PubMed

Kowalewski DJ, Schuster H, Backert L, Berlin C, Kahn S, Kanz L, Salih HR, Rammensee HG, Stevanovic S, Stickel JS. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2015; 112(2):E166-75. (Erratum in: Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6254-6). PubMed

Saini SK, Schuster H, Ramnarayan VR, Rammensee HG, Stevanović S, Springer S. Dipeptides catalyze rapid peptide exchange on MHC class I molecules. Proc Natl Acad Sci U S A. 112(1):202-7, 2015. PubMed

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia. 2015; 29(3):647-59. PubMed

2014

Ziegler H, Welker C, Sterk M, Haarer J, Rammensee HG, Handgretinger R, Schilbach K. Human Peripheral CD4(+) Vδ1(+) γδT Cells Can Develop into αβT Cells. Front Immunol. 5:645, 2014. PubMed

Antonova O, Dolashka P, Toncheva D, Rammensee HG, Floetenmeyer M, Stevanovic S. In vitro antiproliferative effect of Helix aspersa hemocyanin on multiple malignant cell lines. Z Naturforsch C. 69(7-8):325-34, 2014. PubMed

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 515 (7528):577-81, 2014. PubMed

Skabytska Y, Wölbing F, Günther C, Köberle M, Kaesler S, Chen KM, Guenova E, Demircioglu D, Kempf WE, Volz T, Rammensee HG, Schaller M, Röcken M, Götz F, Biedermann T. Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity. 41(5):762-75, 2014 PubMed

Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M, Schmid-Horch B, Salih HR, Kanz L, Rammensee HG, Stevanović S, Stickel JS. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia. 2014 Aug 5. doi: 10.1038/leu.2014.233. [Epub ahead of print]

Feucht J, Leibold J, Halder A, Kayser S, Hartl L, Rammensee HG, Handgretinger R, Feuchtinger T. Differential expression of THELPER 1 cytokines upon antigen stimulation predicts ex vivo proliferative potential and cytokine production of virus-specific T cells following re-stimulation.Transpl Infect Dis. 16(5):713-23, 2014. [PubMed]

Peper JK, Schuster H, Löffler MW, Schmid-Horch B, Rammensee HG, Stevanović S. An impedance-based cytotoxicity assay for real-time and label-free assessment of T-cell-mediated killing of adherent cells. J Immunol Methods. 405:192-8, 2014. PubMed

Overath P, Sturm T, Rammensee HG. Of volatiles and peptides: in search for MHC-dependent olfactory signals in social communication. Cell Mol Life Sci. 71(13):2429-42, 2014. PubMed

 

2013

Boyanova O, Dolashka P, Toncheva D, Rammensee HG, Stevanović S. In vitro effect of molluscan hemocyanins on CAL-29 and T-24 bladder cancer cell lines. Biomed Rep. 1(2):235-238, 2013. PubMed

Rammensee HG, Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev Vaccines. 2(10):1211-7; 2013. PubMed

Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, Khleif SN, Kreiter S, Nielsen M, Rammensee HG, Sahin U, Hinz T, Kalinke U. The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol.31(10):880-2; 2013. PubMed

Lindau D, Mussard J, Rabsteyn A, Ribon M, Kötter I, Igney A, Adema GJ, Boissier MC, Rammensee HG, Decker P.TLR9 independent interferon α production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen.Ann Rheum Dis.2013 [Epub ahead of print]. PubMed

Neumann A, Hörzer H, Hillen N, Klingel K, Schmid-Horch B, Bühring HJ, Rammensee HG, Aebert H, Stevanović S. Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer. Cancer Immunol Immunother. 2013 Sep;62(9):1485-97; 2013. PubMed

Mohme M, Hotz C, Stevanovic S, Binder T, Lee JH, Okoniewski M, Eiermann T, Sospedra M, Rammensee HG, Martin R. HLA-DR15-derived self-peptides are involved in increased autologous T cell proliferation in multiple sclerosis. Brain. 136(Pt 6):1783-98; 2013. PubMed

Lindau D, Mussard J, Wagner BJ, Ribon M, Rönnefarth VM, Quettier M, Jelcic I, Boissier MC, Rammensee HG, Decker P. Primary blood neutrophils express a functional cell surface Toll-like receptor 9. Eur J Immunol. 43(8):2101-13; 2013. PubMed

Geyeregger R, Freimüller C, Stevanovic S, Stemberger J, Mester G, Dmytrus J, Lion T, Rammensee HG, Fischer G, Eiz-Vesper B, Lawitschka A, Matthes S, Fritsch G. Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One. 8(4):e59592; 2013. PubMed

Haen SP, Rammensee HG.The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials. Curr Opin Immunol. 25(2):277-83; 2013. PubMed

Sturm T, Leinders-Zufall T, Maček B, Walzer M, Jung S, Pömmerl B, Stevanović S, Zufall F, Overath P, Rammensee HG. Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons. Nat Commun. 4:1616; 2013. PubMed

Neidert MC, Schoor O, Trautwein C, Trautwein N, Christ L, Melms A, Honegger J, Rammensee HG, Herold-Mende C, Dietrich PY, Stevanović S. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. J Neurooncol. 111(3):285-94; 2013. PubMed

Bugl S, Wirths S, Radsak MP, Schild H, Stein P, André MC, Müller MR, Malenke E, Wiesner T, Märklin M, Frick JS, Handgretinger R, Rammensee HG, Kanz L, Kopp HG. Steady-state neutrophil homeostasis is dependent on TLR4/TRIF signaling. Blood. 121(5):723-33; 2013. PubMed

Singh-Jasuja H, Thiolat A, Ribon M, Boissier MC, Bessis N, Rammensee HG, Decker P. The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. Immunobiology. 218(1):28-39; 2013. PubMed

schliessen

Publications 2012 - 2010

Prof. Dr. rer. nat. Hans-Georg Rammensee

Publications 2012 - 2010

 


2012

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 18(8); 2012. PubMed

Feldhahn M, Dönnes P, Schubert B, Schilbach K, Rammensee HG, Kohlbacher O. miHA-Match: Computational detection of tissue-specific minor histocompatibility antigens. J Immunol Methods 386(1-2):94-100; 2012.PubMed

Singh-Jasuja H, Thiolat A, Ribon M, Boissier MC, Bessis N, Rammensee HG, Decker P. The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. Immunobiology. 2012 Feb 21. [Epub ahead of print]. PubMed

Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, Lohr J, Rammensee HG, Stevanovic S, Trautwein C, Vass V, Walter S, Walker PR, Weinschenk T, Singh-Jasuja H, Dietrich PY. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 135(Pt 4):1042-54; 2012. PubMed

Sartorius T, Lutz SZ, Hoene M, Waak J, Peter A, Weigert C, Rammensee HG, Kahle PJ, Häring HU, Hennige AM. Toll-like receptors 2 and 4 impair insulin-mediated brain activity by interleukin-6 and osteopontin and alter sleep architecture. FASEB J.26(5):1799-809; 2012. PubMed

Wölk B, Trautwein C, Büchele B, Kersting N, Blum HE, Rammensee HG, Cerny A, Stevanovic S, Moradpour D, Brass V. Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands. PLoS One 7(1):e29286; 2012. PubMed

Placke T, Örgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, Salih HR. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells.Cancer Res 72(2):440-8; 2012. PubMed

Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.Int J Cancer 131(1):140-9; 2012. PubMed

André MC, Sigurdardottir D, Kuttruff S, Pömmerl B, Handgretinger R, Rammensee HG, Steinle A. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.Int J Cancer 131(7):1601-10; 2012. PubMed

Hofmann M, Große-Hovest L, Nübling T, Pyż E, Bamberg ML, Aulwurm S, Bühring HJ, Schwartz K, Haen SP, Schilbach K, Rammensee HG, Salih HR, Jung G. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia 26(6):1228-37; 2012. PubMed

Placke T, Örgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, Salih HR. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 72(2): 440-8. 2012. PubMed

 

2011

Haen SP, Gouttefangeas C, Schmidt D, Boss A, Clasen S, von Herbay A, Kosan B, Aebert H, Pereira PL, Rammensee HG. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones 16(5):495-504; 2011. PubMed

Haen SP, Pereira PL, Salih HR, Rammensee HG, Gouttefangeas C. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol. 2011:160250. 2011. PubMed

Lindau D, Rönnefarth V, Erbacher A, Rammensee HG, Decker P. Nucleosome-induced neutrophil activation occurs independently of TLR9 and endosomal acidification: Implications for systemic lupus erythematosus. Eur J Immunol. 41(3):669-81; 2011. PubMed

Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P. Intradermal Vaccinations With RNA Coding for TAA Generate CD8(+) and CD4(+) Immune Responses and Induce Clinical Benefit in Vaccinated Patients. Mol Ther. 19(5):990-9; 2011. PubMed

Stickel JS, Stickel N, Hennenlotter J, Klingel K, Stenzl A, Rammensee HG, Stevanović S. Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol. 20: 11:1; 2011. PubMed

Wagner BJ, Lindau D, Ripper D, Stierhof YD, Glatzle J, Witte M, Beck H, Keppeler H, Lauber K, Rammensee HG, Königsrainer A. Phagocytosis of dying tumor cells by human peritoneal mesothelial cells. J Cell Sci. 124(Pt 10):1644-54; 2011. PubMed

Wagner BJ, Löb S, Lindau D, Hörzer H, Gückel B, Klein G, Glatzle J, Rammensee HG, Brücher BL, Königsrainer A. Simvastatin reduces tumor cell adhesion to human peritoneal mesothelial cells by decreased expression of VCAM-1 and β1 integrin. Int J Oncol. 39(6):1593-600. 2011. PubMed

Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG. Promiscuous survivin peptide induces robust CD4(+) T-cell responses in the majority of vaccinated cancer patients. Int J Cancer. 2011 Aug 19. doi: 10.1002/ijc.26365. [Epub ahead of print]. PubMed

Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A, Kuprash DV, Nedospasov SA, Stenzl A, Aebert H, Wernet D, Stevanović S, Pereira PL, Rammensee HG, Gouttefangeas C. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer. 128(11):2653-62; 2011. PubMed

2010

Autenrieth SE, Linzer TR, Hiller C, Keller B, Warnke P, Köberle M, Bohn E, Biedermann T, Bühring HJ, Hämmerling GJ, Rammensee HG, Autenrieth IB. Immune evasion by Yersinia enterocolitica: differential targeting of dendritic cell subpopulations in vivo. PLoS Pathog. 24;6(11):e1001212; 2010. PubMed

Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, Rammensee HG, Salih HR. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK cell reactivity against human acute myeloid leukemia cells. Blood 115:3058-3069; 2010. PubMed

Sáenz-López P, Gouttefangeas C, Hennenlotter J, Concha A, Maleno I, Ruiz-Cabello F, Cózar JM, Tallada M, Stenzl A, Rammensee HG, Garrido F, Cabrera T. Higher HLA class I expression in renal cell carcinoma than in autologous tissue. Tissue Antigens 75:110-118; 2010. PubMed

Serangeli C, Bicanic O, Scheible MH, Wernet D, Lang P, Rammensee HG, Stevanovic S, Handgretinger R, Feuchtinger T. Ex vivo detection of adenovirus-specific CD4+ T-cell responses to HLA-DR epitopes of the Hexon protein show a contracted specificity of THELPER cells following stem cell transplantation. Virology 397:277-284; 2010. PubMed

schliessen

Publications 2009 - 2005

Prof. Dr. rer. nat. Hans-Georg Rammensee

Publications 2009 - 2005
_________________________________________________________________________________________________________________________________________

 

2009:

Asemissen, A.M., D. Haase, S. Stevanovic, S. Bauer, A. Busse, E. Thiel, H.-G. Rammensee, U. Keilholz, C. Scheibenbogen. 2009. Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2. J. Immunother. 32:370-375.

Attig, S., J. Hennenlotter, G. Pawelec, G. Klein, S.D. Koch, H. Pircher, S. Feyerabend, D. Wernet, A. Stenzl, H.-G. Rammensee, C. Gouttefangeas. 2009. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 69:8412-8419.

Bürk, K., M.-L. Farecki, G. Lamprecht, G. Roth, P. Decker, M. Weller, H.-G. Rammensee, W. Oertel. 2009. Neurological symptoms in patients with biopsy proven celiac disease. Mov. Disord. 24:2358-2362.

Diekmann, J., E. Adamopoulou, O. Beck, G. Rauser, S. Lurati, S. Tenzer, H. Einsele, H.-G. Rammensee, H. Schild, M.S. Topp. 2009. Procesing of two latent membrane protein 1 MHC class I epitoeps requires tripeptidyl peptidase II involvement. J. Immunol. 183:1587-1597.

Feyerabend, S., S. Stevanovic, C. Gouttefangeas, D. Wernet, J. Hennenlotter, J. Bedke, K. Dietz, S. Pascolo, M. Kuczyk, H.-G. Rammensee, A. Stenzl. 2009. Novel multi-peptide vaccination in HLA-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. The Prostate 69:917-927.

Fissolo, N., S. Haag, K.L. de Graaf, O. Drews, S. Stevanovic, H.-G. Rammensee, R. Weissert. 2009. Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients. Mol. Cell. Proteomics 8:2090-2101.

Hennige, A.M., T. Sartorius, S.Z. Lutz, O. Tschritter, H. Preissl, S. Hopp, A. Fritsche, H.-G. Rammensee, P. Ruth, H.-U. Häring. 2009. Insulin-mediated cortical activity in the slow frequency rang eis diminished in obese mice and promotes physical inactivity. Diabetologia 52:2416-2424.

Kuttruff, S., S. Koch, A. Kelp, G. Pawelec, H.-G. Rammensee, A. Steinle. 2009. NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood 113:358-369

Löb, S., A. Königsrainer, D. Zieker, B.L. Brücher, H.-G. Rammensee, G. Opelz, P. Terness. 2009. ISO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58:153-157.

Löb, S., A. Königsrainer, H.-G. Rammensee, G. Opelz, P. Terness. 2009. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nature Rev. Cancer 9:445-452.

Meyer, V.S., O. Drews, M. Günder, J. Hennenlotter, H.-G. Rammensee, S. Stevanovic. 2009. Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J. Proteome Res. 8:3666-3674.

Otz, T., L. Große-Hovest, M. Hofmann, H.-G. Rammensee, G. Jung. 2009. A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28-stimulation and killing of lymphoma cells. Leukemia 23:71-77.

Rammensee, H.-G., H. Singh-Jasuja, N. Emmerich, S. Pascolo. 2009. Cancer vaccines: Some basic considerations. In: Genomic and Personalized Medicine. Vol. 1 (Eds.: Willard, H.F. & G.S.Ginsburg), Elsevier, pp. 573-589.

Stickel, J., A.O. Weinzierl, N. Hillen, O. Drews, M.M. Schuler, J. Hennenlotter, D. Wernet, C.A. Müller, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2009. HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol. Immunother. 58:1407-1417.

Wahlström, J., J. Dengjel, O. Winqvist, I. Targoff, B. Persson, H. Duyar, H.-G. Rammensee, A. Eklund, R. Weissert, J. Grunewald. 2009. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin. Immunol. 133:353-363.

Weide, B., S. Pascolo, B. Scheel, E. Derhovanessian, A. Pflugfelder, T.K. Eigentler, G. Pawelec, I. Hoerr, H.-G. Rammensee, C. Garbe. 2009. Direct injection of protamine-protected mRNA: Results of a phase 1/2 vaccination trial in metastatic melanoma patients. J. Immunother. 32:498-507.

2008:

Feldhahn, M., P. Thiel, M.M. Schuler, N. Hillen, S. Stevanovic, H.-G. Rammensee, O. Kohlbacher. 2008. EpiToolKit – a web server for computational immunomics. Nucleic Acids Res. E-pub.

Herrmann, T., L. Große-Hovest, T. Otz, P.H. Krammer, H.-G. Rammensee, G. Jung. 2008. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res. 68:1221-1227.

Hillen, N., G. Mester, C. Lemmel, A.O. Weinzierl, M. Müller, D. Wernet, J. Hennenlotter, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2008. Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype. Eur. J. Immunol. 38:2993-3003.

Kloss, M., P. Decker, K.M. Baltz, T. Baessler, G. Jung, H.-G. Rammensee, A. Steinle, M. Krusch, H.R. Salih. 2008. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA. J. Immunol. 181:6711-6719.

Löb, S., A. Konigsrainer, R. Schafer, H.-G. Rammensee, G. Opelz, P. Terness. 2008. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111:2152-2154.

Meyer, V.S., W. Kastenmuller, G. Gasteiger, M. Franz-Wachtel, T. Lamkemeyer, H.-G. Rammensee, S. Stevanovic, D. Sigurdardottir, I. Drexler. 2008. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling. J. Immunol. 181:6371-6383.

Rudolf, D., T. Silberzahn, S. Walter, D. Maurer, J. Engelhard, D. Wernet, H.-J. Bühring, G. Jung, B.S: Kwon, H.-G. Rammensee, S. Stevanović. 2008. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen-presenting cells. Cancer Immunol. Immunother. 57:175-183.

Schatz, M., B. Peters, N. Akkad, N. Ullrich, A. Nacarino Martinez, O. Carroll, S. Bulik, H.-G. Rammensee, P. van Endert, H.-G. Holzhütter, S. Tenzer, H. Schild. 2008. Characterizing the N-terminal processing motif of MHC class I ligands. J. Immunol. 180:3210-3217.

Tschiedel, S., C. Gentilini, T. Lange, C. Wölfel, T. Wölfel, V. Lennarz, S. Stevanovic, H.-G. Rammensee, C. Huber, M. Cross, D. Niederwieser. 2008. Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia. Leukemia 22:1542-1550.

Wahlström, J., J. Dengjel, B. Persson, H. Duyar, H.-G. Rammensee, S. Stevanovic, A. Eklund, R. Weissert, J. Grunewald. 2008. Identification of HLA-DR-bound peptides prsented by human bronchoalveolar large cells in sarcoidosis. J. Clin. Invest. 117:3576-3582.

Waldhauer, I., D. Goehlsdorf, G. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H.-G. Rammensee, A. Steinle. 2008. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 68:6368-6376.

Weide, B., J.-P. Carralot, A. Reese, B. Scheel, T.K. Eigentler, I. Hoerr, H.-G. Rammensee, C. Garbe, S. Pascolo. 2008. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31:180-188.

Weide, B., C. Garbe, H.-G. Rammensee, S. Pascolo. 2008. Plasmid DNA and messenger RNA-based anti-cancer vaccination. Immunol. Lett. 115:33-42.

Weinzierl, A.O., D. Maurer, F: Altenberend, N. Schneiderhan-Marra, K. Klingel, O. Schoor, D. Wernet, T. Joos, H.-G. Rammensee, S. Stevanović. 2008. A cryptic vascular endothelial growth factor T-cell epitope: Identification and characterization by mass spectrometry and T-cell assays. Cancer Res. 68:2447-2454.

Weinzierl, A., D. Rudolf, N. Hillen, S. Tenzer, P. van Endert, H. Schild, H.-G. Rammensee, S. Stevanović. 2008. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur. J. Immunol. 38:1503-1510.

Weinzierl, A., D. Rudolf, D. Maurer, D. Wernet, H.-G. Rammensee, S. Stevanović, K. Klingel. 2008. Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses. J. Gen. Virol. 89:2090-2097.

Weinzierl, A., G. Szalay, H. Wolburg, M. Sauter, H.-G. Rammensee, R. Kandolf, S. Stevanovic, K. Klingel. 2008.  Effective chemokine secretion by dendritic cells and expansion of cross-presenting CD4-/CD8+ dendritic cells define a protective phenotype in the mouse model of coxsackievirus myocarditis. J. Virol. 82:8149-8160.

Yokoyama, Y., F. Grünebach, S.M. Schmidt, A. Heine, M. Häntschel, S. Stevanovic, H.-G. Rammensee, P. Brossart. 2008. Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clin. Cancer Res. 14:5503-5511.

2007:

Adamopoulou E., J. Diekmann, E. Tolosa, G. Kuntz, H. Einsele, H.-G. Rammensee,  M. S. Topp. 2007. Human CD4+ T Cells Displaying Viral Epitopes Elicit a Functional Virus-Specific Memory CD8+ T Cell Response. J. Immunol.  178: 5465-5472.

Baltz, K.M., M. Krusch, A. Bringmann, P. Brossart, F. Mayer, M. Kloss, T. Baessler, I. Kumbier, A. Peterfi, S.Kupka, S. Kroeber, D. Menzel, M.P. Radsak, H.-G. Rammensee, H.R. Salih. 2007. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 21:2442-2454.

Boss, C. N., F. Grünebach, K. Brauer, M Häntschel, V. Mirakaj, T. Weinschenk, S. Stevanović, H.-G. Rammensee, P. Brossart. 2007. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin. Cancer Res. 13:3347-3355.

Gouttefangeas, C., A. Stenzl, S. Stevanović, H.-G. Rammensee. 2007. Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother. 56:117-128.

Probst J., B. Weide, B. Scheel, B. J. Pichler, I. Hoerr, H.-G. Rammensee, S. Pascolo. 2007. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 14:1175-1180.

Röck, F., K. P. Hadeler, H.-G. Rammensee, P. Overath. Quantitative analysis of murine urine volatiles: in search of MHC-dependent differences. 2007. PloS ONE 2:e429.

Wahlström J. J. Dengjel, B. Persson, H. Düyar, H.-G. Rammensee, S. Stevanović, A. Eklund, R. Weissert, J. Grunewald. 2007. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J. Clin. Invest. 117:3576-3582.

Weinzierl, A.O., C. Lemmel, O. Schoor, M. Müller, T. Krüger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingel, H.-G. Rammensee, S. Stevanović. 2007. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol. Cell. Proteomics 6:102-113.

2006:

Asemissen, A.-M., U. Keilholz, S. Tenzer, M. Müller, S. Walter, S. Stevanovic, H. Schild, A. Letsch, E. Thiel, H.-G. Rammensee, C. Scheibenbogen. 2006. identification of a highly immunogenic HLA-A*01-binding T-cell epitope of WT1. Clin. Cancer Res. 12:7476-7482.

Decker, P., I. Kötter, R. Klein, B. Berner, H.-G. Rammensee. 2006. Monocyte-dervied dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology 45:1087-1095.

Dengjel, J., M.-D. Nastke, C. Gouttefangeas, G. Gitsioudis, O. Schoor, F. Altenberend, M. Müller, B. Krämer, A. Missiou, M. Sauter, J. Hennenlotter, D. Wernet, A. Stenzl, H.-G. Rammensee, K. Klingel, S. Stevanovic. 2006. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin. Cancer Res. 12:4163-4170.

Osterloh, P., K. Linkemann, S. Tenzer, H.-G. Rammensee, M.P. Radsak, D.H. Busch, H. Schild. 2006. Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc. Natl. Acad. Sci. USA 103:5042-5047.

Probst, J., S. Brechtel, B. Scheel, I. Hoerr, G. Jung, H.-G. Rammensee, S. Pascolo. 2006. Characterization of the ribonuclease activity on the skin surface. Genetic Vaccines Ther. 4:4 (on-line).

Rammensee, H.-G. 2006. Peptides made to order. Immunity 25:693-695.

Rammensee, H.-G. 2006. Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer. Immunol. Cell Biol. 84:290-294.

Rechtsteiner, G., T. Warger, M. Hofmann, H.-G. Rammensee, H. Schild, M.P. Radsak. 2006. Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo. Eur. J. Immunol. 36:2613-2623.

Röck, F., S. Mueller, U. Weimar, H.-G. Rammensee, P. Overath. 2006. Comparative analysis of volatile constituents from mice and their urine. J. Chem. Ecol. 32:1333-1346.

Rönnefarth, V.M., A.I.M. Erbacher, T. Lamkemeyer, J. Madlung, A. Nordheim, H.-G. Rammensee, P. Decker. 2006. TLR2/TLR4-independent neutrophil activation and recruitment upon endocytosis of nucleosomes reveals a new pathway of innate immunity in systemic lupus erythematosus. J. Immunol. 177:7740-7749.

Scheel, B., S. Aulwurm, J. Probst, L. Stitz, I. Hoerr, H.-G. Rammensee, M. Weller, S. Pascolo. 2006. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. 36:2807-2816.

Warger, T., N. Hilf, G. Rechtsteiner, P. Haselmayer, D.M. Carrick, H. Jonuleit, P. von Landenberg, H.-G. Rammensee, C.V. Nicchitta, M.P. Radsak, H. Schild. 2006. Interaction of TLR2 and TLR4 ligands with the N-terminal domain of GP96 amplifies innate and adaptive immune responses. J. Biol. Chem. 281:22545-22553.

2005:

Carralot, J.-P., C. Dumrese, R. Wessel, R. Riessen, I. Autenrieth, S. Walter, O. Schoor, S. Stevanovic, H.-G. Rammensee, S. Pascolo. 2005. CD8+ T cells specific for a potential HLA-A*0201 epitope from Chlamydophila pneumoniae are present in the PBMCs from infected patients. Int. Inmunol. 17:591-597.

Carralot, J.-P., B. Weide, O. Schoor, J. Probst, B. Scheel, R. Teufel, I. Hörr, C. Garbe, H-G. Rammensee, S. Pascolo. 2005. Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet. Vaccines Ther. 3:6.

Decker, P., H. Singh-Jasuja, S. Haager, I. Kotter, H.-G. Rammensee. 2005. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J. Immunol. 174:3326-3334.

Dengjel, J., H.-G. Rammensee, S. Stevanovic. 2005. Glycan side chains on naturally presented MHC class II ligands. J. Mass Spectrom. 40:100-104.

Dengjel, J., O. Schoor, R. Fischer, M. Reich, M. Kraus, M. Müller, K. Kreymborg, F. Altenberend, J. Brandenburg, H. Kalbacher, R. Brock, C. Driessen, H.-G. Rammensee, S. Stevanovic. 2005. Autophagy promotes MHC class II presentation of peptides form intracellular source proteins. Proc. Natl. Acad. Sci. USA 102:7922-7927.

Dittmann, J., K. Keller-Matschke, T. Weinschenk, T. Kratt, T. Heck, H.-D. Becker, S. Stevanovic, H.-G. Rammensee, C. Gouttefangeas. 2005. CD8+ T-cell response against MUC-1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol., Immunother. 54:750-758.

Grosse-Hovest, L., W. Wick, R. Minoia, M. Weller, M, H.-G. Rammensee, G. Brem, G. Jung. 2005. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int. J. Cancer 117:1060-1064.

Herter, S., P. Osterloh, N. Hilf, G. Rechtsteiner, J. Höhfeld, H.-G. Rammensee, H. Schild. 2005. Dendritic cell aggresome-like-induced structure formation and delayed antigen presentation coincide in influenza virus-infected dendritic cells. J. Immunol. 175:891-898.

Jung, G., Herrmann, T., Grosse-Hovest, L., Salih, H.R., Rammensee, H.-G.: Monoclonal and bispecific antibodies as novel therapeutics. Chapter XI. In: Los, M., Gibson, S.B. (Eds) Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Springer, Berlin, 229 – 242 (2005)

Kramer, B.F., O. Schoor, T. Kruger, C. Reichle, M. Muller, T. Weinschenk, J. Hennenlotter, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2005. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol. Ther. 4:943-948.

Krüger, T., O. Schoor, C. Lemmel, B. Krämer, C. Reichle, J. Dengjel, T. Weinschenk, M. Müller, J. Hennenlotter, A. Stenzl, H.-G. Rammensee, S. Stevanovic. 2005. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol., Immunother. 54:826-836.

Nastke, M.-D., L. Herrgen, S. Walter, D. Wernet, H.-G. Rammensee, S. Stevanovic. 2005. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell. Mol. Life Sci. 62:77-86.

Neumeister, B., M. Faigle, D. Spitznagel, A. Mainka, A. Ograbek, H. Wieland, N. Mannowetz, H.-G. Rammensee. 2005. Legionella pneumophila down-regulates MHC class I expression of human monocytic host cells and thereby inhibits T cell activation. Cell. Mol. Life Sci. 62:578-588.

Pascolo, S., F. Ginhoux, N. Laham, S. Walter, O. Schoor, J. Probst, P. Rohrlich, F. Obermayr, P. Fisch, O. Danos, R. Ehrlich, F.A. Lemonnier, H.-G. Rammensee. 2005. The non-classical HLA class I molecule HFE does not influence the NK-like activity contained in fresh human PBMCs and does not interact with NK cells. Int. Immunol.17:117-122.

Ramirez, S.R., H. Singh-Jasuja, T. Warger, S. Braedel-Ruoff, N. Hilf, K. Wiemann, H.G. Rammensee, H. Schild. Glycoprotein 96-actiated dendritic cells induce a CD8-biased T-cell response. 2005. Cell Stress Chaperones 10:221-229.

Scheel, B., R. Teufel, J. Probst, J.-P. Carralot, J. Geginat, M. Radsak, D. Jarrossay, H. Wagner, G. Jung, H.-G. Rammensee, I. Hörr, S. Pascolo. 2005. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur. J. Immunol. 35:1557-1566.

Schilbach, K., G. Kerst, S. Walter, M. Eyrich, D. Wernet, R. Handgretinger, W. Xie, H.-G. Rammensee, I. Müller, H.-J. Bühring, D. Niethammer. 2005. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: Artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood 106:144-149.

Schuler, M.M., P. Donnes, M.-D. Nastke, O. Kohlbacher, H.-G. Rammensee, S. Stevanovic. 2005. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics 57:816-820.

Tammiruusu, A., A. Haveri, S. Pascolo, R. Lahesmaa, S. Stevanovic, H.-G. Rammensee, M. Sarvas, M. Puolakkainen, J.M. Vuola. 2005. Clearance of Chlamydia pneumoniae infection in H-2 class I-/- human leucocyte antigen-A2.1 monochain transgenic mice. Scand. J. Immunol. 62:131-139.

Tenzer, S., B. Peters, S. Bulik, O. Schoor, C. Lemmel, M.M. Schatz, P.M. Kloetzel, H.-G. Rammensee, H. Schild, H.G. Holzhütter. 2005. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol. Life Sci. 62:1025-1037.

Teufel, R., J.-P. Carralot, B. Scheel, J. Probst, S. Walter, G. Jung, I. Hörr, H.-G. Rammensee, S. Pascolo. 2005. Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T lymphocytes in vitro. Cell Mol. Life Sci. 62:1755-1762.

Walter, S., G. Bioley, H.J. Bühring, S. Koch, D. Wernet, A. Zippelius, G. Pawelec, P. Romero, S. Stevanovic, H.-G. Rammensee, C. Gouttefangeas. 2005. High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur. J. Immunol. 35:2876-2885.

Wiemann, K., H.W. Mittrücker, U. Feger, S.A. Welte, W.M. Yokoyama, T. Spies, H.-G. Rammensee, A. Steinle. 2005. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175:720-729.

schliessen

Important publications (selection)

Prof. Dr. rer. nat. Hans-Georg Rammensee

Important publications (selection)
____________________________________________________________________________________________________________________________________________

Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H. 2012. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 18(8):1254-61, 2012.  PubMed

Lob, S., A. Konigsrainer, H. G. Rammensee, G. Opelz, and P. Terness. 2009. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat. Rev. Cancer 9:445. Pubmed

Feyerabend, S., S. Stevanovic, C. Gouttefangeas, D. Wernet, J. Hennenlotter, J. Bedke, K. Dietz, S. Pascolo, M. Kuczyk, H. G. Rammensee, and A. Stenzl. 2009. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69:917. Pubmed

Weide, B., J. P. Carralot, A. Reese, B. Scheel, T. K. Eigentler, I. Hoerr, H. G. Rammensee, C. Garbe, and S. Pascolo. 2008. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 31:180. Pubmed

Osterloh, P., K. Linkemann, S. Tenzer, H. G. Rammensee, M. P. Radsak, D. H. Busch, and H. Schild. 2006. Proteasomes shape the repertoire of T cells participating in antigen-specific immune responses. Proc. Natl. Acad. Sci. U. S. A 103:5042.Pubmed

Rammensee, H.-G. 2006. Peptides made to order. Immunity 25:693-695. Pubmed

Dengjel, J., O. Schoor, R. Fischer, M. Reich, M. Kraus, M. Muller, K. Kreymborg, F. Altenberend, J. Brandenburg, H. Kalbacher, R. Brock, C. Driessen, H. G. Rammensee, and S. Stevanovic. 2005. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc. Natl. Acad. Sci. U. S. A 102:7922. Pubmed

Rammensee, H.-G. 2004. New and Views: Immunology: Protein surgery. Nature 427:203-204. Pubmed

Lemmel, C., S. Weik, U. Eberle, J. Dengjel, T. Kratt, H. D. Becker, H. G. Rammensee, and S. Stevanovic. 2004. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 22:450. Pubmed

Dengjel, J., P. Decker, O. Schoor, F. Altenberend, T. Weinschenk, H. G. Rammensee, and S. Stevanovic. 2004. Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur. J Immunol. 34:3644. Pubmed

Drexler, I., C. Staib, W. Kastenmuller, S. Stevanovic, B. Schmidt, F. A. Lemonnier, H. G. Rammensee, D. H. Busch, H. Bernhard, V. Erfle, and G. Sutter. 2003. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. U. S. A 100:217. Pubmed

Rammensee, H.-G. 2002. Survival of the fitters. Nature 419:443-445. Pubmed

Weinschenk, T., C. Gouttefangeas, M. Schirle, F. Obermayr, S. Walter, O. Schoor, R. Kurek, W. Loeser, K. H. Bichler, D. Wernet, S. Stevanovic, and H. G. Rammensee. 2002. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62:5818. Pubmed

Rammensee, H. G., T. Weinschenk, C. Gouttefangeas, and S. Stevanovic. 2002. Towards patient-specific tumor antigen selection for vaccination. Immunol. Rev. 188:164. Pubmed

Rammensee, H.-G., T. Friede, and S. Stevanovic. 1995. MHC ligands and peptide motifs. First listing. Immunogenetics 41:178-228. Pubmed

Falk, K., O. Rötzschke, S. Stevanovic, G. Jung, and H.-G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296. Pubmed
Comment in  J Immunol. 2006;177(5):2741-7. Pubmed

Rötzschke, O., K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger, G. Jung, and H.-G. Rammensee. 1990. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 348:252-254. Pubmed

Falk, K., O. Rötzschke, and H.-G. Rammensee. 1990. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 348:248-251. Pubmed

Rötzschke, O., K. Falk, H.-J. Wallny, S. Faath, and H.-G. Rammensee. 1990. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 249:283-287. Pubmed

Wallny, H.-J. and H.-G. Rammensee. 1990. Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 343:275-278. Pubmed

Rammensee, H.-G. R. Kroschewski, and B. Frangoulis. 1989. Clonal anergy induced in mature Vß6+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells. Nature 339:541-544. Pubmed

Deres, K., H. Schild, K.-H. Wiesmüller, G. Jung, and H.-G. Rammensee. 1989. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342:561-564. Pubmed

Rammensee, H. G., P. J. Robinson, A. Crisanti, and M. J. Bevan. 1986. Restricted recognition of beta 2-microglobulin by cytotoxic T lymphocytes. Nature 319:502-504. Pubmed

Rammensee, H. G. and M. J. Bevan. 1984. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 308:741-744. Pubmed

 

 

schliessen

Scientific Profile

Prof. Dr. rer. nat. Hans-Georg Rammensee

Scientific Profile
_______________________________________________________________________________________________________________________________________________________________________________________________________

I started to work on immunology in 1979, with the specific aim of using tumor immunology to fight against cancer. My first research projects were on minor histocompatibility antigens, which revealed some similarity to tumor antigens: weak immunogens, MHC-restricted, nature completely unknown at that time. After contributing to the areas of genetics and immune regulation (“veto cells”), I showed that central tolerance to such antigens is MHC restricted (Rammensee HG, Bevan MJ., Nature 1984; 308:741). Later, I identified the first minor H antigen (Rammensee HG et al., Nature 1986; 319:502).
After setting up my own research group, we 1) showed that minor H antigens are peptides presented by MHC (Nature 1990; 343:275, Science 1990; 249:283); 2) identified the first naturally processed viral T cell epitopes (Nature 1990; 348:252; 634 citations), 3) for the first time eluted and identified peptides directly from MHC, and discovered the nature of MHC peptide specificity (“motifs”) (Nature 1991; 351:290; 1882 citations; featured in “pillars of immunology”, J Immunol. 2006 Sep 1; 177(5):2741-7), 4) showed that MHC itself contributes to processing of peptides (Nature 1990; 348:248), 5) demonstrated, for the first time, induction of T cell anergy in vivo (Nature 1989; 339: 541; 542 citations), 6) used a covalent peptide/TLR-ligand compound for efficient immunization (Nature 1989; 342:561; 521 citations). Building on the MHC/peptide work, we were the first group to exactly predict T cell epitopes. We then systematically developed bioinformatic tools for this purpose, e.g., our database SYFPEITHI, which is the gold standard in this field (Immunogenetics 1995; 41:178; 1212 citations).
Several of my former PhD students or postdocs have achieved leading positions. E.g., my first PhD student, Hansjörg Schild, is now chair of Immunology at the University of Mainz; Christian Münz is full professor for Experimental Immunology at the University of Zürich, Dept. of Pathology, and thus, the successor of Rolf Zinkernagel; Alexander Steinle is full professor for Molecular Medicine at the University of Frankfurt/M; Olaf Rötzschke is group leader at the Singapore Immunology Network (BIOPOLIS); Eckhard Lammert is full professor and chair of the Institute for Zoophysiology at the University of Düsseldorf; and Harpreet Singh is CSO of immatics biotechnologies.
More recently, I am frequently invited to write comments on new developments in immunology by the leading journals, e.g., Rammensee HG. Peptides made to order. Immunity. 2006; 25:693; Rammensee HG. Immunology: protein surgery. Nature. 2004; 427:203; Rammensee HG. Survival of the fitters. Nature. 2002; 419:443.
In recent years, we have combined basic research on MHC biology with translational research; thus, I could build upon 20 years of research by finally bringing tumor immunology into clinical practice, together with expert clinicians. This work has led already to two flourishing spin-off companies (immatics and CureVac), both in clinical phase I and phase II trials. Please look in the ASCO 2010 (June 4th – 8th in Chicago) reports on their latest results! I now intend to use the next 10 years to bring truly individualized cancer immunotherapy (something big pharma is not interested so far) into the clinic, taking advantage of the latest technological advances in genome sequencing and peptidome analysis.

schliessen

Scientific Career History

Prof. Dr. rer. nat. Hans-Georg Rammensee

Scientific Career History

2008 – presentDirector, Interfaculty Institute for Cell Biology, University of Tübingen, Germany
2013ERC-Advanced Grant (EU) for the project: Mutaediting: Mutation-driven immunoediting of human cancer? 
2010 Co-founder of the biotechnology enterprise SYNIMMUNE GmbH
2000Co-founder of the biotechnology enterprises immatics GmbH and CureVac GmbH
1996 – presentChair, Department of Immunology (Full Professor, C4), Interfaculty Institute for Cell Biology, University of Tübingen, Germany
1993 – 1996Head of Department, Tumor-Virus-Immunology Section, German Cancer Research Center (DKFZ), Heidelberg; appointment as Professor, University of Heidelberg
1991Habilitation in immunology at the University of Tübingen
1988 – 1993Academic teaching duties at the Universities of Tübingen and Heidelberg
1987 – 1993Group leader at the Department of Immunogenetics, Max Planck Institute for Biology, Tübingen, Germany
1985 – 1987Scientific Member of the Basel Institute for Immunology (Minor H antigens and self tolerance)
1982 – 1985Postdoctoral research fellow in the laboratory of Michael J. Bevan, Ph.D., at Scripps Clinic, La Jolla, CA, USA (Self tolerance of cytotoxic T lymphocytes)
1980 – 1982PhD thesis in the laboratory of Professor Dr. Jan Klein at the Max-Planck-Institute for Biology, Tübingen, Germany. (Minor histocompatibility antigens)
1980Diploma thesis in the laboratory of Professor Dr. Jan Klein at the Max-Planck-Institute for Biology, Tübingen, Germany
1974 – 1980Study of biology at the University of Tübingen, Germany

schliessen

Scholarships, awards, qualifications

Prof. Dr. rer. nat. Hans-Georg Rammensee

Scholarships, awards, qualifications

2014 – 2020
2008 – 2014
Co-opted member of the Scientific Council of the Paul Ehrlich Foundation / (Download Brochure)
2014German Cancer Aid Award 2013 (for exceptional achievements in the field of oncology)(background)
2013The Hansen Family Award (background)
2012Deputy Site Coordinator, German Consortium for Translational Cancer Research (DKTK). Joint initiative of the German Ministry of Education and Research (BMBF), the participating federal states, German Cancer Aid and the German Cancer Research Center (DKFZ)
2011 – presentChairman of the Integrated Research Training Group (IRTG): Immunotherapy of the SFB685
2011 – presentMember of the Scientific Advisory Board, RCI Regensburg Center for Interventional Immunology
2011 – presentMember of the Scientific Advisory Board, Cluster for Individualized Immunointervention (CI3)
2009 – presentMember, Scientific Advisory Committee, International Society for Dendritic Cell and Vaccine Science
2008 – presentMember of the Baden-Württemberg Steering Committee for the organization of joint projects between the National University of Singapore and universities in Baden-Württemberg
2008 – presentAdvisory Board Member of BayImmuNet (Immune Therapy Network of the Bavarian State Ministry of Sciences, Research and the Arts)
2007 – 2011Member, HFSP Council of Scientists
2008Ceppellini Lecture Award of the European Federation of Immunogenetics
2006 – presentMember of the Academy of Sciences and Literature, Mainz
2006 – 2010Panel member of the Scientific Council of the European Research Council
2005 – presentChairman of the Sonderforschungsbereich 685: Immunotherapy: Molecular basis and clinical application (SFB685)
2002 – 2011Chairman of the Graduiertenkolleg 794: Graduate School for Cellular Mechanisms of Immune-associated Processes (GRK794)
2002 – presentCo-founder and association member of the Association for Cancer Immunotherapy (CIMT)
2002 – presentMember of the Academy of Cancer Immunology
2002 – 2004Research Dean of the Faculty of Medicine, Tübingen
1998 – presentMember of the Cooperation Program in Cancer Research
(German Cancer Research Center Heidelberg and the Ministry of Science, Israel)
1997 – 2004Vice-Chairman and Chairman of the Sonderforschungsbereich 510: Hemopoietic Stem Cell Biology and Antigen Processing
1997 – 2001Chairman of the Graduiertenkolleg : Cell Biology in Medicine
1997Rose Payne Distinguished Scientist Award
1996Paul Ehrlich Prize
1996Ludwig Darmstaedter Prize
1993Robert Koch Prize
1992Avery Landsteiner Prize
1991Gottfried Wilhelm Leibniz Prize
1991Wilhelm und Maria Meyenburg Prize
1988Heinz-Maier-Leibnitz Prize


schliessen

  • The story about the moose

    The structure of the HLA-A2 molecule (left), which was reported in 1987 by Bjorkman and colleagues, inspired Hajo Schild three years later to accentuate its outline in order to show the resemblance of this structure to the head of a moose (center). Later, a cartoon drawn by a caricaturist based in Tübingen, Sepp Buchegger, appeared in the local newspaper reminding us of our own moose picture. Sepp Buchegger then kindly agreed to design a logo for us which depicted a moose’s head with horns that could be envisaged as a peptide receptacle. The design has represented the official logo of our department for very many years.

  • ........The "birth" of the moose logo

Prof. Dr. rer. nat. Hans-Georg Rammensee

Prof. Dr. rer. nat. Hans-Georg Rammensee

University of Tübingen
Interfaculty Institute for Cell Biology
Department of Immunology
Auf der Morgenstelle 15
72076 Tuebingen

Phone: +49-7071-29 87628
Fax:     +49-7071-29 5653
Email:   rammensee (@) uni-tuebingen.de

Information für interessierte Krebspatienten

Liebe Krebspatientin, lieber Krebspatient,

(25. Juli 2014)

 

wir sind eine Einrichtung der Grundlagenforschung. Wir sind keine Krebsklinik, und ich selbst bin kein Arzt, sondern Naturwissenschaftler.

Seit vielen Jahren bemühen wir uns um neue Krebsimmuntherapien; wir haben dabei bereits Erfolge vorzuweisen: Von Ausgründungen aus meiner Abteilung, den Firmen immatics und CureVac, wurden bereits Studien durchgeführt. Informationen über aktuell laufende Studien finden Sie unter https://clinicaltrials.gov/. 

Unser Ziel ist,  auf den bisherigen Erfahrungen aufzubauen, und eine Strategie zu entwickeln, die - aufgrund unserer wissenschaftlichen Überlegungen - noch weit bessere Erfolge zeigen müsste. Nämlich eine individualisierte Immuntherapie, bei der zunächst vom Tumorgewebe eines jeden Patienten die geeigneten Zielstrukturen ermittelt werden (diese sind nämlich bei jedem Patienten anders) um diese dann als sogenannte Peptide synthetisch herzustellen und dem Patienten als Impfstoff zu verabreichen. Für jeden Patienten soll also eigens ein individueller Impfstoff hergestellt werden. Die am weitesten fortgeschrittenen Projekte befassen sich mit dem Hirntumor Glioblastom (GAPVAC; www.gapvac.eu) und dem Leberkrebs hepatozelluläres Karzinom (HEPAVAC, www.hepavac.eu), beide mit mehreren europäischen Partnern und von der Europäischen Union gefördert. Die ersten Patienten können jedoch erst 2015 bzw. 2016 eingeschlossen werden, vor allem deshalb, weil wir bis vor Kurzem an der Lösung unseres Hauptproblems gearbeitet haben:  Solche Impfpeptide, auch wenn sie nur für einen einzigen Patienten gemacht werden, müssen als Arzneimittel nach dem Arzneimittelgesetz (AMG) hergestellt werden. Seit vielen Jahren bemühten wir uns um eine behördliche Erlaubnis für eine solche Herstellung; wir haben ein eigenes Gebäude mit Reinräumen errichtet, haben diese Erlaubnis jedoch erst vor Kurzem erreicht (genauer: für Impfstoffzubereitungen mit bis zu 5 Peptiden im März, für solche mit bis zu 10 Peptiden am 15. 07. 2014. Es dauerte so lange,  weil die zuständigen Behörden uns wie einen Großpharmahersteller behandeln (müssen), da das AMG solche "Einzelherstellungen" bisher nicht vorhergesehen hat. 

Wir können nun die beiden obengenannten Studien durchführen. Leider können wir darüber hinaus derzeit keine weiteren Studien konkretisieren, vor allem aus Kapazitätsgründen; wir arbeiten jedoch daran. Für Sie konkret bedeutet das, dass wir Ihnen derzeit keine Behandlung Ihrer Krankheit anbieten können. In Zukunft hoffen wir jedoch in der Lage zu sein, Sie diesbezüglich an die mit uns eng zusammenarbeitenden klinischen Abteilungen am Universitätsklinikum Tübingen bzw. an weitere Universitätskliniken verweisen zu können.

Ich bitte Sie deshalb, von Anrufen oder Anfragen wegen Behandlungsmöglichkeiten für Sie oder Ihre Angehörigen an unsere Abteilung abzusehen; wir werden Sie an dieser Stelle von neuen Entwicklungen bzw. neuen klinischen Studien informieren. Sollten Sie jedoch Informationen zu aktuellen Studien und Therapiemöglichkeiten am Universitätsklinikum Tübingen, Kontakte zu spezialisierten Ärzten oder Selbsthilfegruppen benötigen, so könne Sie sich gerne an den „Krebswegweiser Tübingen" (über www.medizin.uni-tuebingen.de/itz/) wenden, wo Ihnen kompetente Ansprechpartner zu diesen Themen zur Verfügung stehen.

Mit freundlichen Grüßen

Prof. Dr. rer. nat. Hans-Georg Rammensee (NICHT Dr. med.!)

 

schliessen

German Consortium for Translational Cancer Research (DKTK)

Prof. Dr. Hans-Georg Rammensee is member of the
German Consortium for Translational Cancer Research (DKTK)

and overall coordinator of the research program
Cancer immunology of therapeutic vaccines

Comprehensive Cancer Center (CCC) Tübingen

Prof. Rammensee is board member of the
Comprehensive Cancer Center (CCC) Tübingen

Interfaculty Institute for Cell Biology / third floor: Department of Immunology

Auf der Morgenstelle 15